Literature DB >> 15360017

Rituximab-induced remission of a gastric MALT lymphoma.

Yvonne H Datta1, Bal Kampalath, David G Binion.   

Abstract

Gastric MALT lymphoma is usually associated with H. pylori infection, and responds to treatment with antibiotics and a proton pump inhibitor. We report a case of H. pylori negative gastric MALT lymphoma. The patient was followed conservatively for 2 years until she developed gastrointestinal bleeding with significant anemia. She was treated with rituximab 375 mg/m2 weekly for four doses, which resulted in a biopsy proven complete remission. Rituximab therapy is a reasonable, well tolerated treatment alternative for MALT lymphomas not associated with H. pylori.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15360017     DOI: 10.1080/1042819032000159889

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  A case of Helicobacter heilmannii-associated primary gastric mucosa-associated lymphoid tissue lymphoma achieving complete remission after eradication.

Authors:  Takuma Okamura; Yugo Iwaya; Shuichi Yokosawa; Tomoaki Suga; Norikazu Arakura; Takehisa Matsumoto; Naoko Ogiwara; Kayoko Higuchi; Hiroyoshi Ota; Eiji Tanaka
Journal:  Clin J Gastroenterol       Date:  2013-01-09

Review 2.  Therapeutic antibodies against cancer.

Authors:  Mark J Adler; Dimiter S Dimitrov
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

3.  Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.

Authors:  Nadeem Chaudhary; Howard Ozer; David Huard; Stan Lightfoot; Sikandar Mesiya
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.